1. Home
  2. DFH vs IMMX Comparison

DFH vs IMMX Comparison

Compare DFH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

BUY

Current Price

$9.00

Market Cap

764.1M

ML Signal

BUY

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$8.52

Market Cap

784.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFH
IMMX
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
764.1M
784.8M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
DFH
IMMX
Price
$9.00
$8.52
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
N/A
★ $24.30
AVG Volume (30 Days)
★ 1.5M
1.4M
Earning Date
11-02-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.37
N/A
Revenue
★ $4,322,848,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.50
N/A
P/E Ratio
$25.82
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.30
$2.85
52 Week High
$23.80
$15.10

Technical Indicators

Market Signals
Indicator
DFH
IMMX
Relative Strength Index (RSI) 40.97 36.11
Support Level $7.30 $7.96
Resistance Level $16.47 $8.97
Average True Range (ATR) 0.61 0.53
MACD 0.09 -0.05
Stochastic Oscillator 46.94 23.53

Price Performance

Historical Comparison
DFH
IMMX

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: